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In the past few years there have been significant advances which have changed the face of chronic urticaria. In this
review, we aim to update physicians about clinically relevant advances in the classification, diagnosis and management
of chronic urticaria that have occurred in recent years. These include clarification of the terminology used to describe
and classify urticaria. We also detail the development and validation of instruments to assess urticaria and understand
the impairment on quality-of-life and the morbidity caused by this disease. Additionally, the approach to management
of chronic urticaria now focuses on evidence-based use of non-impairing, non-sedating H1-antihistamines given initially
in standard doses and if this is not effective, in up to 4-fold doses. For urticaria refractory to H1-antihistamines,
omalizumab treatment has emerged as an effective, safe option.
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Urticaria is characterized by wheals of various sizes sur-
rounded by flares (erythema). Mast cells play a central
role in the pathophysiology. Their activation through
immunologic or non-immunologic processes induces de-
granulation that results in release of potent preformed
inflammatory mediators such as histamine, and newly-
synthesized mediators such as leukotrienes and prosta-
glandins. The main biologic effects of these mediators
are pruritus, increased vascular permeability, and tis-
sue edema. Pruritus, the primary symptom, results
from mediator-induced sensory nerve impulses travel-
ling to the cerebrum and is associated with significant
morbidity [1-3].
In this review, we provide an update on clinically rele-
vant advances in the classification, investigations, and
management of chronic urticaria that have occurred in
the past few years (see list of key points for insights and
advances).* Correspondence: gsussman@rogers.com
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unless otherwise stated.List of key points for insights and advances
 The term chronic spontaneous urticaria (CSU)
replaces the term chronic idiopathic urticaria (CIU).
 Second-generation non-impairing non-sedating
H1-antihistamines are recommended for first-line
treatment of CSU.
 Up-dosing with second-generation non-impairing
non-sedating H1-antihistamines (to 2, 3, or 4 times
the licensed dose) is recommended as second-line
treatment in CSU.
 Omalizumab (anti-IgE antibody) effectively and safely
induces remission in H1-antihistamine-resistant CSU
and is used as third-line treatment for this indication.Review
Definitions, classification, and epidemiology
Acute urticaria, defined as hives lasting less than 6 weeks,
can occur spontaneously, or be associated with acute
viral infections or allergic reactions to foods, medica-
tions, or insect stings or bites. Chronic urticaria, defined
as hives occurring intermittently for at least 6 weeks, is
further classified as spontaneous, i.e. chronic spontan-
eous urticaria (CSU), or inducible by physical stimulial. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cible. The prevalence of CSU is 0.5% to 1% in the gen-
eral population. It occurs most commonly in women,
and has a peak age of onset between 20 and 40 years.
There is associated angioedema, defined as asymmetric
non-dependent swelling of sub-mucosal tissues, in 33%-
66% of patients with CSU [1-3] (Figure 2).
Etiology and pathogenesis
Spontaneous implies an endogenous cause; therefore, it
is not surprising that in most patients with CSU, an ex-
ternal trigger such as an allergen cannot be identified
[1,2]. Approximately 45% of patients have an auto-
immune component associated with antibodies to the
IgE receptor alpha subunit or to IgE itself on mast cell
surfaces. Also, approximately 25% of CSU patients have
associated thyroid auto-antibodies; however, in CSU,
these antibodies do not correlate with altered thyroid
function [1-3].
Patients with CSU can have high levels of anxiety. Psy-
chiatric co-morbidities including mood, anxiety, and
personality disorders have been reported [4]. These co-
morbidities are often major contributors to quality of life
impairment [5]. It has been suggested that psychosocial
factors may play a role in the pathogenesis of CSU [4,6].Figure 1 Chronic spontaneous urticaria.Disease course and prognosis
CSU, by definition, persists for at least six weeks and its
course is typically characterized by exacerbations and re-
missions. From 10% to 50% of patients have CSU for
longer than 5 years. Longer duration of illness is asso-
ciated with severe disease. Elevated plasma levels of
C-reactive protein, prothrombin 1 and 2, and D-dimer
are reported to function as markers of CSU severity [7].
Practice guidelines
Urticaria guidelines published in 2014 include new infor-
mation on CSU classification, investigations, instruments
available to grade severity and impact on quality of life,
as well as new recommendations for management [2,3].
Investigations
Diagnosis of CSU is based on a thorough history and
physical examination. Specific questioning about use of
non-steroidal anti-inflammatory drugs(NSAIDs)is im-
portant because up to 30% to 50% of CSU patients have
exacerbations associated with NSAID ingestion [1,2]. All
patients require a complete physical examination, in-
cluding visualization and confirmation of characteristic
pruritic, raised erythematous lesions (Figure 1). Serial
photographs are useful for documenting the extent and
Table 1 Classification of chronic urticaria subtypes
(presenting with wheals, angioedema, or both)
Acute urticaria Chronic urticaria
Characteristics Persists for less
than 6 weeks
Chronic spontaneous urticaria
Persists for at least 6 weeks
Inducible urticaria
Occurs in response to an
identifiable (physical) trigger.
Subtypes include:
● Physical urticaria (dermographism,
cold urticaria, delayed pressure






Sussman et al. Allergy, Asthma & Clinical Immunology  (2015) 11:7 Page 3 of 7severity of the urticaria. The frequency, pattern, and dur-
ation of lesions should be recorded.
Inducible urticarial lesions typically persist for less
than two hours, with the exception of delayed pressure
urticaria, which can last for more than 24 hours. Patients
with CSU should be tested for dermographic urticaria
using a tongue depressor or, if available, a standardized
instrument, to stroke the skin firmly and induce wheal
formation (Figure 3). Physical challenge tests for cold-
induced urticaria using an ice cube or, if available, a
standardized instrument, or tests for other subtypes of
inducible urticaria, should be considered in patients with
a history of exacerbations from these stimuli (Figure 4,
Table 2).
Guidelines now recommend that the initial investiga-
tion of CSU should generally be limited to a complete
blood count (CBC) and differential, and measurement of
inflammation markers such as erythrocyte sedimentation
rate (ESR) or C-reactive protein (CRP) [2,3] (Table 2).Figure 2 Angioedema.Depending on the history, other investigations may be
indicated (Table 2). A skin biopsy should be performed
in patients with atypical urticaria; for example, those
with burning or painful hives that persist for longer than
72 hours, suggestive of urticarial vasculitis. Patients with
hyperpigmented lesions should have the skin stroked
firmly to elicit Darier’s sign (whealing) suggestive of cu-
taneous mastocytosis and a baseline serum tryptase level
to rule out mastocytosis; a lesional biopsy should be per-
formed if indicated. Allergy skin tests generally have lim-
ited diagnostic value. The autologous serum skin test
(ASST), performed by intradermal injection of autolo-
gous serum using careful sterile technique, is rarely used
in practice. A positive ASST suggests the presence of
auto-antibodies to the high-affinity IgE receptor or to
IgE; however, this test is not specific for CSU [7]. Assays
for auto-antibodies to the high-affinity IgE receptor or
to IgE are only available in specialized research laborator-
ies. Newer tests for auto-antibodies are being developed.
Impact on quality of life
CSU has been shown to cause significant morbidity and
to have a negative impact on all aspects of a patient’s life,
including work, school, social activities, diet and sleep.
In an attempt to quantify this, new instruments have
been developed to grade urticaria severity. The Urticaria
Activity Score, recorded daily for a week (UAS7), is
Figure 4 The dermographometer, or FricTest®, (left), a standardized instrument for diagnosis of dermatographic urticaria and the
TempTest® (right) a new tool for diagnosing cold urticaria. Both instruments are produced by Moxie GmbH (Berlin, Germany).
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score (Table 3). A UAS7 score of 6 or less is generally
considered to indicate well controlled chronic urticaria.
The impact of urticaria on quality of life can be assessed
by a Quality of Life questionnaire (CU-Q2oL) [8], whichTable 2 Recommended investigations in urticaria according t
Type Subtype Initial tests





CBC with differential and
Inducible urticaria Cold urticaria Cold provocation and th
ice cube to the skin for 5
use a TempTest; urticaria
Delayed pressure urticaria Pressure test
Heat urticaria Heat provocation and th




a tongue depressor or, if
Aquagenic urticaria Wet cloths at body temp
for 20 min
Cholinergic urticaria Exercise and hot bath pr
Contact urticaria
CBC, complete blood count; ESR, erythrocyte sedimentation rate; CRP, C-reactive pr
*Acute urticaria and angioedema can also occur in the context of anaphylaxis. Such pa
episode, eg. foods, stinging insect venoms or medications (references [2,3]).has been validated in Canada in both English and
French. Validated angioedema activity scores and a QoL
score for angioedema are also available and are import-
ant tools for assessing the disability associated with dis-
figuring angioedema [9]. Recently, the urticaria controlo type and subtype
More extensive tests
None*
ESR or CRP (i) Allergen skin testing, and measurement
of allergen-specific IgE levels are seldom
required in CSU. Measurement of IgG levels
to foods has no diagnostic value. (ii) functional
autoantibodies; (iii) thyroid hormones and
autoantibodies; (iv) physical tests; (v) tryptase;
(vi) autologous serum skin test; (vii) lesional
skin biopsy
reshold test: apply an
min, or, if available,
appears on re-warming
CBC with differential and ESR/CRP cryoproteins
None
reshold test None
fferent wave lengths Rule out other light-induced dermatoses
stroking skin firmly with





otein; NSAID, non-steroidal anti-inflammatory drug.
tients should be tested to allergens relevant to the history of their anaphylactic
Table 3 The Urticaria Activity Score (UAS7) for assessing disease activity in chronic spontaneous urticaria
Score Wheals Pruritus
0 None None
1 Mild (<20 wheals/24 h) Mild (present but not annoying or troublesome)
2 Moderate (20–50 wheals/24 h) Moderate (troublesome but does not interfere with normal daily activity or sleep)
3 Intense (>50 wheals/24 h or large confluent areas of wheals) Intense (severe pruritus, which is sufficiently troublesome to interfere with normal
daily activity or sleep)
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urticaria. This tool permits the assessment of chronic
urticaria, angioedema, and inducible urticaria [10].
Management
The overall goal is complete symptom control and dis-
ease remission. Factors that exacerbate CSU, including
stress and ingestion of NSAIDs should be avoided.
Second-generation non-impairing non-sedating H1-anti-
histamines, which are effective, safe, and inexpensive,
are recommended as first-line treatment. They should
be taken on a regular daily basis, not on an as-needed
basis. There is no advantage in using more than one H1-
antihistamine at the same time (Table 4) [2,3,11,12].
Up-dosing with two, three, or four times the licensed dos-
age, for example, desloratadine up to 20 mg, is suggested as
second-line treatment to be implemented if the licensed
dosage of an H1-antihistamine is not effective [13-15].
First-generation sedating impairing H1-antihistamines
are no longer recommended for use in urticaria, because
they potentially interfere with restful (rapid eye move-
ment) sleep, cause hangovers or “morning-after” effects,
impair learning and memory, and reduce work effi-
ciency. Impairment is not necessarily accompanied by
sedation [10,16].Table 4 Urticaria treatment algorithm
First line
Second-generation non-impairing non-sedating antihistamines if symptoms
persist after 2 weeks
↓
Second-line
Increase dosage up to four-times the standard dose1,2 of a second-generatio
non-impairing non-sedating antihistamine or, if symptoms persist after 4 furth




Add-on to second-line treatment: omalizumab, cyclosporine A, consider
specialist referral to allergist/dermatologist. Exacerbation: oral corticosteroid
1Standard dose means the usual recommended dose.
2Double the initial recommended pediatric dose in case of non-response.
3Can cause sedation at these doses.Montelukast can be used as add-on second-line treat-
ment in H1-antihistamine refractory CSU, although
some clinical trials have not shown a significant benefit
[17]. H2-antihistamines are no longer recommended as
first-, second-, or third-line treatment, as the level of evi-
dence supporting their use is low [18].
At any stage of treatment, a short course of an oral
corticosteroid can be added on an empirical basis to
provide rescue treatment of a CSU exacerbation. One
example of a suggested corticosteroid treatment regimen
is an initial dose of 0.3 – 0.5 mg/kg of prednisone or
equivalent, followed by tapering of the dose in half every
3–7 days over a maximum duration of 2–4 weeks [19].
Recommended third-line treatments include omalizu-
mab, or off-label use of cyclosporine A [2,3,17,20-25].
A trial of cyclosporine A is recommended as add-on
treatment to a second-generation H1-antihistamine in
patients who fail to respond adequately to treatment
with an H1-antihistamine alone (high level of evidence).
Administered in a dose of 3–5 mg/kg divided twice
daily, cyclosporine can lead to complete remission of ur-
ticaria; however, regular monitoring of blood pressure,
complete blood count, and renal function, followed by
dose adjustment when needed, is advised in order to re-
duce the possibility of toxicity [17].Standard dosing. Desloratadine 5 mg OD. Loratadine 10 mg OD.
Cetirizine HCI 10 mg OD. Fexofenadine HCI 60 mg BID
n
er
Up-dosing to the limit specified, eg. Desloratadine up to 20 mg OD.
Cetirizine HCI up to 40 mg OD3. Montelukast 10 mg OD
Re-evaluate response to treatment every 3 months
Omalizumab 150 mg or 300 mg, SC Q4 wks. Cyclosporine
A 2.5-5 mg/kg/day and taper with response
Oral corticosteroids, for example, 0.3-0.5 mg/kg of prednisone
or equivalent, followed by tapering of the dose in half every
3–7 days over a maximum duration of 2–4 weeks
Sussman et al. Allergy, Asthma & Clinical Immunology  (2015) 11:7 Page 6 of 7Omalizumab, an anti-IgE humanized monoclonal anti-
body, can be used as add-on therapy to a non-sedating
second-generation H1-antihistamine as a third-line treat-
ment for CSU (high level of evidence) [20,21]. Its efficacy
and safety have been demonstrated in large, well-designed,
randomized double-blind, placebo-controlled trials in pa-
tients with CSU refractory to H1-antihistamine treatment
[20,21]. Some studies suggest that 300 mg omalizumab
injected subcutaneously every four weeks is the effective
dose; however, others suggest that 150 mg is effective [21].
Additional investigations are needed to define the optimal
dose, dose schedule, and duration of treatment [24].These
issues are important from a cost-effectiveness perspective.
In 2014, in Canada, the United States and in Europe, oma-
lizumab was approved by regulatory agencies for treat-
ment of H1-antihistamine-refractory chronic urticaria in
adults and adolescents age 12 years and older [25].
Use of other pharmacologic agents as third-line treat-
ments, including hydroxychloroquine, dapsone, mycophe-
nolate mofentil, tacrolimus, intravenous gamma-globulin
and sulfasalazine, is based mainly on case reports and un-
controlled trials [15].
CSU is self-limited and eventually remits completely
in most patients. Until remission occurs, whether this
takes months, years, or decades, the therapeutic goal re-
mains complete relief of itching and other symptoms.Conclusions
The urticarias are a heterogeneous group of disorders,
classified as acute or chronic (which can be spontaneous
or inducible). In the new terminology, the term “spontan-
eous” replaces the term “idiopathic” and the term “indu-
cible” replaces the term “physical”. Chronic spontaneous
urticaria (CSU) affects 0.5% to 1% of the population, and
has a negative impact on all aspects of quality of life.
After the correct clinical diagnosis is made, most pa-
tients need only limited testing. Careful history, physical
examination, and follow-up will identify those who re-
quire additional investigations.
Second-generation non-impairing non-sedating H1-anti-
histamines are recommended as first-line medications for
initial treatment. New effective and safe therapeutic op-
tions have emerged for treatment of patients with CSU re-
fractory to the standard dosage of an H1-antihistamine.
Up-dosing with a second-generation non-impairing non-
sedating H1-antihistamine such as desloratadine in 2, 3, or
4 times the licensed dosage is recommended as second-
line treatment. Omalizumab injections subcutaneously at
monthly intervals are recommended as a novel effective
and safe therapeutic option for CSU refractory to the
above. Research in progress will help to define some spe-
cific aspects of these new approaches and further establish
their place in the treatment algorithm.Consent
Written informed consent was obtained for publication
of the accompanying images in this review. A copy of
the written consent is available for review by the Editor-
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